Dr. Krzysztof Brzozka joined Selvita in 2007 as a specialist responsible for evaluation, due diligence and in-licensing of research projects. In 2009 he became a Project Manager of the first anticancer project initiated at Selvita and in subsequent years initiated further research projects, also in additional therapeutic indications. In January 2012 he was appointed to the position of Chief Scientific Officer and Member of the Management Board and is currently responsible for development of internal pipeline of novel, small molecule therapies across various indications. Dr. Brzozka holds a PhD degree from Ludwig Maximilian University in Munich (Germany) and an MSc degree in Biotechnology, specializing in Molecular Biology, from the Jagiellonian University in Krakow (Poland). He also completed a two-year Executive MBA at Stockholm University School of Business and the Cracow University of Economics Business School. In the years 2003 – 2007, Dr. Brzozka conducted research at the Ludwig Maximilian University in the field of intracellular signaling, pathogen defense mechanisms leading to the immune system inhibition and the innate immune response.

 Dr. Brzozka has a unique interdisciplinary expertise in development of projects in the preclinical phase, ranging from in silico studies, medical chemistry and, in vitro and in vivo molecular biology studies and toxicology.